AIM2 and brain neoplasm: Subsequently, however, 38 of 39 (97%) and 28 of 28 (100%) animals collectively in the 3 control groups — scrambled shRNA/non-TTFields-treated (Scr/NT), dual STING-AIM2 shRNA knockdown/TTFields-treated (DKD/TTF), and DKD/non-TTFields-treated (DKD/NT) — developed progressive brain tumors and succumbed by day 100 (median overall survival [mOS] of 45 days) in the KR158-luc model (Figure 7B and Table 1) and by day 40 (mOS of 27 days) in the GL261-luc model (Figure 8A and Table 2), respectively.